Nerelimomab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458282962

| image =

| type = mab

| mab_type = mab

| source = o

| target = TNF alpha

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 162774-06-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 1911H0X9KJ

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D05146

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Nerelimomab is a mouse monoclonal antibody acting as a TNF inhibitor.{{Cite web | title = WHO Drug Information | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list76.pdf | access-date = 2009-09-24 | archive-url = https://web.archive.org/web/20120219143254/http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list76.pdf | archive-date = 2012-02-19 | url-status = dead }}{{cite journal | vauthors = Huang L, Du B, Cui X, Zhao H, Feng Y, Xu Z, Long J, Yuan J, You F | title = Nerelimomab Alleviates Capsaicin-Induced Acute Lung Injury by Inhibiting TNF Signaling and Apoptosis | journal = Pharmaceuticals | location = Basel, Switzerland | volume = 17 | issue = 12 | date = December 2024 | page = 1694 | pmid = 39770536 | pmc = 11676931 | doi = 10.3390/ph17121694 | doi-access = free }}